152 related articles for article (PubMed ID: 11806282)
1. [Role of plasminogen activator inhibitor type 1 in tumor angiogenesis].
Bajou K; Devy L; Masson V; Albert V; Frankenne F; Noël A; Foidart JM
Therapie; 2001; 56(5):465-72. PubMed ID: 11806282
[TBL] [Abstract][Full Text] [Related]
2. [Role of PAI-1 plasminogen activator inhibitor in tumor invasion and angiogenesis].
Bajou K
Bull Mem Acad R Med Belg; 2002; 157(5-6):313-8. PubMed ID: 12557575
[TBL] [Abstract][Full Text] [Related]
3. Wound-induced migration of MDA-MB-435 and SKOV-3 cancer cells is regulated by plasminogen activator inhibitor-1.
Whitley BR; Church FC
Int J Oncol; 2005 Sep; 27(3):749-57. PubMed ID: 16077925
[TBL] [Abstract][Full Text] [Related]
4. Plasminogen activator inhibitor type-1 mutants regulate angiogenesis of human umbilical and lung vascular endothelial cells.
Chorostowska-Wynimko J; Swiercz R; Skrzypczak-Jankun E; Selman SH; Jankun J
Oncol Rep; 2004 Dec; 12(6):1155-62. PubMed ID: 15547731
[TBL] [Abstract][Full Text] [Related]
5. Metastasis of transgenic breast cancer in plasminogen activator inhibitor-1 gene-deficient mice.
Almholt K; Nielsen BS; Frandsen TL; Brünner N; Danø K; Johnsen M
Oncogene; 2003 Jul; 22(28):4389-97. PubMed ID: 12853975
[TBL] [Abstract][Full Text] [Related]
6. Host-derived plasminogen activator inhibitor-1 (PAI-1) concentration is critical for in vivo tumoral angiogenesis and growth.
Bajou K; Maillard C; Jost M; Lijnen RH; Gils A; Declerck P; Carmeliet P; Foidart JM; Noel A
Oncogene; 2004 Sep; 23(41):6986-90. PubMed ID: 15286708
[TBL] [Abstract][Full Text] [Related]
7. [Roles of serine proteases and matrix metalloproteinases in tumor invasion and angiogenesis].
Masson V
Bull Mem Acad R Med Belg; 2006; 161(5):320-6. PubMed ID: 17283905
[TBL] [Abstract][Full Text] [Related]
8. Quantitative RT-PCR assays for the determination of urokinase-type plasminogen activator and plasminogen activator inhibitor type 1 mRNA in primary tumor tissue of breast cancer patients: comparison to antigen quantification by ELISA.
Biermann JC; Holzscheiter L; Kotzsch M; Luther T; Kiechle-Bahat M; Sweep FC; Span PN; Schmitt M; Magdolen V
Int J Mol Med; 2008 Feb; 21(2):251-9. PubMed ID: 18204793
[TBL] [Abstract][Full Text] [Related]
9. Urokinase plasminogen activator and plasminogen activator inhibitor type-1 in nonsmall-cell lung cancer: relation to prognosis and angiogenesis.
Offersen BV; Pfeiffer P; Andreasen P; Overgaard J
Lung Cancer; 2007 Apr; 56(1):43-50. PubMed ID: 17207889
[TBL] [Abstract][Full Text] [Related]
10. Plasminogen activator inhibitor-I and tumour growth, invasion, and metastasis.
Durand MK; Bødker JS; Christensen A; Dupont DM; Hansen M; Jensen JK; Kjelgaard S; Mathiasen L; Pedersen KE; Skeldal S; Wind T; Andreasen PA
Thromb Haemost; 2004 Mar; 91(3):438-49. PubMed ID: 14983218
[TBL] [Abstract][Full Text] [Related]
11. The urokinase-system in tumor tissue stroma of the breast and breast cancer cell invasion.
Hildenbrand R; Schaaf A
Int J Oncol; 2009 Jan; 34(1):15-23. PubMed ID: 19082473
[TBL] [Abstract][Full Text] [Related]
12. Expression of active plasminogen activator inhibitor-1 reduces cell migration and invasion in breast and gynecological cancer cells.
Whitley BR; Palmieri D; Twerdi CD; Church FC
Exp Cell Res; 2004 Jun; 296(2):151-62. PubMed ID: 15149846
[TBL] [Abstract][Full Text] [Related]
13. Lack of association between level of Plasminogen Activator Inhibitor-1 and estimates of tumor angiogenesis in early breast cancer.
Offersen BV; Riisbro R; Knoop A; Brünner N; Overgaard J;
Acta Oncol; 2007; 46(6):782-91. PubMed ID: 17653901
[TBL] [Abstract][Full Text] [Related]
14. Plasminogen activator inhibitor type 1 promotes fibrosarcoma cell migration by modifying cellular attachment to vitronectin via alpha(v)beta(5) integrin.
Takahashi T; Suzuki K; Ihara H; Mogami H; Kazui T; Urano T
Semin Thromb Hemost; 2005 Jun; 31(3):356-63. PubMed ID: 16052409
[TBL] [Abstract][Full Text] [Related]
15. Tumour-associated urokinase-type plasminogen activator (uPA) and its inhibitor PAI-1 in normal and neoplastic tissues of patients with squamous cell cancer of the oral cavity - clinical relevance and prognostic value.
Hundsdorfer B; Zeilhofer HF; Bock KP; Dettmar P; Schmitt M; Kolk A; Pautke C; Horch HH
J Craniomaxillofac Surg; 2005 Jun; 33(3):191-6. PubMed ID: 15878520
[TBL] [Abstract][Full Text] [Related]
16. Urokinase plasminogen activator system: a multifunctional role in tumor progression and metastasis.
Choong PF; Nadesapillai AP
Clin Orthop Relat Res; 2003 Oct; (415 Suppl):S46-58. PubMed ID: 14600592
[TBL] [Abstract][Full Text] [Related]
17. The urokinase plasminogen activator system: a rich source of tumour markers for the individualised management of patients with cancer.
Duffy MJ; Duggan C
Clin Biochem; 2004 Jul; 37(7):541-8. PubMed ID: 15234235
[TBL] [Abstract][Full Text] [Related]
18. Haemostatic factors occupy new territory: the role of the urokinase receptor system and kininogen in inflammation.
Chavakis T; Kanse SM; May AE; Preissner KT
Biochem Soc Trans; 2002 Apr; 30(2):168-73. PubMed ID: 12023845
[TBL] [Abstract][Full Text] [Related]
19. Expression of urokinase-type plasminogen activator, urokinase-type plasminogen activator receptor and plasminogen activator inhibitors in patients with renal cell carcinoma: correlation with tumor associated macrophage and prognosis.
Ohba K; Miyata Y; Kanda S; Koga S; Hayashi T; Kanetake H
J Urol; 2005 Aug; 174(2):461-5. PubMed ID: 16006865
[TBL] [Abstract][Full Text] [Related]
20. Plasminogen activator inhibitor-1 in tumor growth, angiogenesis and vascular remodeling.
Stefansson S; McMahon GA; Petitclerc E; Lawrence DA
Curr Pharm Des; 2003; 9(19):1545-64. PubMed ID: 12871067
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
